Welcome to our dedicated page for Clene news (Ticker: CLNN), a resource for investors and traders seeking the latest updates and insights on Clene stock.
Clene Inc. reports developments as a late clinical-stage biopharmaceutical company developing clean-surfaced nanotechnology therapeutics for neurodegenerative diseases. Through Clene Nanomedicine Inc., the company focuses on improving mitochondrial health and protecting neuronal function in amyotrophic lateral sclerosis, multiple sclerosis and Parkinson’s disease.
Recurring news centers on CNM-Au8®, an investigational nanocrystal suspension designed to target mitochondrial function and the NAD pathway while reducing oxidative stress. Company updates include ALS biomarker and expanded-access data, FDA meeting and regulatory communications, operating and financial results, registered direct financing activity, shareholder communications, voting matters and investor-conference presentations.
Clene Inc. (NASDAQ: CLNN) will host a webinar on July 14, 2021, at 4:30 p.m. ET, focusing on 'Cellular Energetic Failure' related to ALS and MS. Expert speakers include Professors Matthew Kiernan and Benjamin Greenberg, who will discuss current treatment options and unmet needs in these conditions. Clene's management will present their lead candidate, CNM-Au8, a gold nanocrystal suspension aimed at improving neuroprotection and energy in cells. The webinar will also cover milestone expectations, including data from the Phase 2 RESCUE-ALS trial.
Clene Inc. (NASDAQ: CLNN) announced its inclusion in the U.S. small-cap Russell 2000® and all-cap Russell 3000® Indexes effective June 28, 2021. This membership is based on the company's market capitalization as of May 7, 2021, and will last for one year.
Rob Etherington, President and CEO, stated that this recognition will enhance the visibility of Clene's stock and attract more institutional investors. The firm aims to achieve key milestones, such as announcing topline data from its Phase 2 RESCUE-ALS trial later this year, which may increase shareholder value.
Clene Inc. (NASDAQ: CLNN) announced that Rob Etherington, President and CEO, will present at the Raymond James Human Health Innovation Conference on June 22, 2021, at 11:20 a.m. ET. A webcast of the presentation will be available on Clene's website. Clene is a clinical-stage biopharmaceutical company focused on neurodegenerative diseases, utilizing nanotechnology to address bioenergetic failure. Their lead drug candidate, CNM-Au8, is in Phase 3 trials for ALS and Phase 2 trials for multiple sclerosis and Parkinson’s disease.
Clene Inc. (NASDAQ: CLNN) announced plans to lease a 75,000 sq. ft. facility in Elkton, Maryland, to enhance its manufacturing capabilities ahead of positive data expected in H1 2022 from its Phase 3 trial for CNM-Au8, targeting amyotrophic lateral sclerosis (ALS). The company secured a Loan Agreement providing up to $30 million and a private placement (PIPE) to raise $9.25 million through the sale of common stock. Together, these initiatives are projected to increase Clene's cash position significantly to support its clinical and manufacturing expansion.
Clene Inc. (NASDAQ: CLNN) has appointed David J. Matlin as Chairman of the Board, succeeding Shalom Jacobovitz, who will remain on the Board. Matlin, who has been a Director since 2020, brings significant experience as the CEO of MatlinPatterson Global Advisers and a background in financial markets. Under Matlin's leadership, Clene aims to advance its clinical pipeline, notably a registration trial for ALS, with topline results expected in H1 2022. Clene focuses on treating neurodegenerative diseases through its innovative drug candidate, CNM-Au8.
Clene Inc. (NASDAQ: CLNN) received a Healthy Longevity Catalyst Award from the U.S. National Academy of Medicine for its bioenergetic nanocatalyst, CNM-Au8, aimed at treating aging-related neuronal deficits and Alzheimer's disease. Clene will utilize the award to fund preclinical studies, exploring CNM-Au8's potential in additional neurodegenerative diseases. Currently, CNM-Au8 is undergoing multiple clinical trials for amyotrophic lateral sclerosis, Parkinson’s, and multiple sclerosis, showcasing promise in enhancing neuroprotection and energy in neuronal cells.
Clene Inc. (NASDAQ: CLNN) announced promising preliminary blinded efficacy data from its ongoing Phase 2 RESCUE-ALS clinical trial, which evaluates CNM-Au8 in early symptomatic ALS patients. Data presented at the ENCALS 2021 meeting show that 34%, 26%, and 18% of participants demonstrated improvement in motor neuron function at Weeks 12, 24, and 36, respectively, differing from expected declines in prior studies. Correlation analyses indicate that these improvements are linked to less clinical worsening. Unblinded topline results are anticipated in the second half of 2021.
Clene Inc. (NASDAQ: CLNN) reported promising interim Phase 2 data for its drug CNM-Au8, suggesting potential neurological improvements in multiple sclerosis (MS) patients. The company secured a grant from the Michael J. Fox Foundation to expedite CNM-Au8's development for Parkinson's disease. Clene holds $48 million in cash as of March 31, 2021, sufficient to cover operations into mid-2022. However, the company reported a net loss of $39.8 million for Q1 2021, a significant increase from the previous year, largely due to unrealized losses and rising R&D expenses.
Clene Inc. (NASDAQ: CLNN) has received Notices of Allowance from the U.S. Patent and Trademark Office for two patent applications related to its clean-surfaced nanocrystal therapeutic technology. This expands its patent portfolio to over 160, enhancing protection for its lead drug candidate, CNM-Au8. Currently undergoing evaluation in seven clinical studies targeting ALS, MS, and Parkinson’s disease, CNM-Au8 is pivotal for Clene's future, with Phase 3 trial results expected in H1 2022. Rob Etherington, CEO, emphasized the value of their growing intellectual property as the clinical pipeline advances.
Clene Inc. (NASDAQ: CLNN) reported its full-year 2020 results, highlighting progress in its clinical trials for CNM-Au8, a neuroprotective nanocatalyst aimed at treating ALS, MS, and Parkinson's disease. Interim Phase 2 data showed over 40% improvement in motor neuron function in ALS patients. Clene has $59.3M in cash as of December 31, 2020, expected to fund operations into mid-2022. The company anticipates topline data from key trials in 2021, including the HEALEY ALS Platform trial and studies in MS and PD.